Graded Cardiac Response Criteria for AL Amyloidosis: The Impact of Depth of Cardiac Response on Survival

被引：3

作者：

Muchtar, Eli ^{[1
]}

Dispenzieri, Angela ^{[1
]}

Wisniowski, Brendan ^{[2
]}

Palladini, Giovanni ^{[3
]}

Milani, Paolo ^{[4
]}

Merlini, Giampaolo ^{[5
]}

Schönland, Stefan ^{[6
]}

Veelken, Kaya ^{[7
]}

Hegenbart, Ute ^{[8
]}

Kumar, Shaji ^{[1
]}

Kastritis, Efstathios ^{[9
]}

Dimopoulos, Meletios A. ^{[10
]}

Liedtke, Michaela ^{[11
]}

Witteles, Ronald ^{[12
]}

Sanchorawala, Vaishali ^{[13
]}

Szalat, Raphael ^{[14
]}

Landau, Heather J. ^{[15
]}

Petrlik, Erica ^{[16
]}

Lentzsch, Suzanne ^{[17
]}

Coltoff, Alexander ^{[18
]}

Bladé, Joan ^{[19
]}

Cibeira, M. Teresa ^{[20
]}

Cohen, Oliver ^{[21
,22
]}

Foard, Darren

Wechalekar, Ashutosh D.

Gertz, Morie A. ^{[1
]}

机构：

[1] Mayo Clin, Div Hematol, Rochester, MN USA

[2] Natl Amyloidosis Ctr, London, England

[3] Fondazione IRCCS Policlinico San Matteo, Amyloidosis Res & Treatment Ctr, Pavia, Italy

[4] Univ Pavia, Fdn IRCCS Policlinico San Matteo, Pavia, Italy

[5] Univ Pavia, Dept Mol Med, Fdn IRCCS Policlinico San Matteo, Amyloidosis Res & Treatment Ctr, Pavia, Italy

[6] Univ Heidelberg Hosp, Dept Med, Amyloidosis Ctr, Heidelberg, Germany

[7] Univ Heidelberg Hosp, Amyloidosis Ctr, Heidelberg, Germany

[8] Univ Heidelberg Hosp, Internal Med Hematol, Oncol Rheumatol, Heidelberg, Germany

[9] Univ Athens, Sch Med, Dept Clin Therapeut Natl & Kapodistrian, Athens, Greece

[10] Univ Athens, Dept Clin Therapeut, Sch Med, Athens, Greece

[11] Stanford Univ, Div Hematol, Dept Med, Stanford, CA USA

[12] Stanford Univ, Stanford Amyloid Ctr, Sch Med, Stanford, CA USA

[13] Boston Univ, Amyloidosis Ctr, Boston Med Ctr, Sch Med, Boston, MA USA

[14] Boston Univ, Dept Hematol & Med Oncol, Med Ctr, Boston, MA USA

[15] Mem Sloan Kettering Canc Ctr, Dept Med, Adult Bone Marrow Transplant Serv, New York, NY USA

[16] Mem Sloan Kettering Canc Ctr, New York, NY USA

[17] Columbia Univ, Div Hematol Oncol, Dept Med, Irving Med Ctr, New York, NY USA

[18] Columbia Univ, Div Hematol Oncol, Med Ctr, New York, NY USA

[19] Hosp Clin Barcelona, Dept Hematol, Amyloidosis & Myeloma Unit, Barcelona, Spain

[20] Hosp Clin Barcelona, Barcelona, Spain

[21] UCL, Royal Free Hosp Campus, Natl Amyloidosis Ctr, Med Sch, London, England

[22] UCL, London, England

来源：

BLOOD | 2021年 / 138卷

关键词：

D O I：

10.1182/blood-2021-149222

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：7

共 50 条

[21] AL CARDIAC AMYLOIDOSIS WITH MULTIPLE CARDIAC MASSES: A RARE CASE OF PROGRESSION OF DISEASE DESPITE HEMATOLOGIC RESPONSE
Sharp, Madeline
Rearick, Corey
Nosenchuck, Clare M.
Franz, Joseph
Levenson, Joshua Eric
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2024, 83 (13) : 2845 - 2845
[22] Should We Amplify Cardiac Response Criteria in Patients with Cardiac Light-Chain Amyloidosis Treated with Bortezomib?
Vazquez, J.
Durante, A.
Hernandez, E.
Monivas Palomero, V.
Mingo, S.
Sayago, I.
Garcia Pavia, P.
Alonso-Pulpon, L.
Segovia Cubero, J.
JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2017, 36 (04): : S169 - S169
[23] Patients with a cardiac complete response in AL amyloidosis have survival rates similar to those of a matched general population
Muchtar, Eli
Geyer, Susan
Merlini, Giampaolo
Gertz, Morie A.
BLOOD, 2024, 144 (07) : 790 - 793
[24] Persisting Cardiac Dysfunction and Quality of Response Predict Survival in Patients with AL Amyloidosis Who Respond to Upfront Therapy
Palladini, Giovanni
Milani, Paolo
Basset, Marco
Russo, Francesca
Foli, Andrea
Merlini, Giampaolo
BLOOD, 2017, 130
[25] B type natriuretic peptide (BNP) as a marker of cardiac response in AL amyloidosis
Palladini, G.
Foli, A.
Milani, P.
Albertini, R.
Sarais, G.
Perlini, S.
Russo, P.
Bragotti, L. Zenone
Salinaro, F.
Obici, L.
Moratti, R.
D'Eril, G. V. Melzi
Merlini, G.
AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS, 2010, 17 : 85 - 85
[26] Diagnosis of Cardiac Amyloidosis: Is Imaging Enough? Response
Garcia-Gonzalez, Pilar
del Puig Cozar-Santiago, Maria
Maceira, Alicia M.
REVISTA ESPANOLA DE CARDIOLOGIA, 2017, 70 (07): : 617 - 617
[27] Device therapy for cardiac amyloidosis does not impact survival
Lin, Grace
Webster, Tracy L.
Grogan, Martha
Dispenzieri, Angela
Kyle, Robert
Brady, Peter A.
CIRCULATION, 2007, 116 (16) : 337 - 337
[28] Impact of tricuspid regurgitation on survival in patients with cardiac amyloidosis
Fagot, Jerome
Lavie-Badie, Yoan
Blanchard, Virginie
Fournier, Pauline
Galinier, Michel
Carrie, Didier
Lairez, Olivier
Cariou, Eve
ESC HEART FAILURE, 2021, 8 (01): : 438 - 446
[29] Safety of delivery of bortezomib to patients with cardiac AL Amyloidosis: The impact of cardiac monitoring
Attwood, C.
Sado, D.
Rice, C.
Streetly, M.
El-Najjar, I.
Wechalekar, A.
Gunning, D.
Deppe, S.
Benjamin, R.
Cuthill, K.
BRITISH JOURNAL OF HAEMATOLOGY, 2019, 185 : 97 - 98
[30] Safety Profile Of Bortezomib Impacts Survival Of Cardiac AL Amyloidosis
Van de Wyngaert, Zoe
Vanoutryve, Greg
Herbaux, Charles
Fouquet, Guillemette
Demarquette, Helene
Bonnet, Sarah
Beauvais, David
Guidez, Stephanie
Lamblin, Nicolas
Hachulla, Eric
Launay, David
Terriou, Louis
Hivert, Benedicte
Wemeau, Mathieu
Leleu, Xavier
BLOOD, 2013, 122 (21)

← 1 2 3 4 5 →